Tarsus Pharmaceuticals (TARS) Stock Statistics & Valuation Metrics

Tarsus Pharmaceuticals has a market cap or net worth of $1.99B. The enterprise value is $1.92B.

Tarsus Pharmaceuticals has 42,014,236 shares outstanding. The number of shares has decreased by -2.65% in one year.

Tarsus Pharmaceuticals’s return on equity (ROE) is -0.51 and return on invested capital (ROIC) is -40.60%.

The current PE Ratio of Tarsus Pharmaceuticals is -18.02. Tarsus Pharmaceuticals’s PEG ratio is 0.54.

In the last 12 months, Tarsus Pharmaceuticals had revenue of 182.95M and earned -115.55M in profits. Earnings per share was -3.07.

In the last 12 months, operating cash flow was -65.89M and capital expenditures -6.98M, giving a free cash flow of -72.87M billion.

Tarsus Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Tarsus Pharmaceuticals upcoming earnings date is Aug 7, 2025, TBA Not Confirmed.

Tarsus Pharmaceuticals as a current ratio of 4.42, with Debt / Equity ratio of 0.00%

In the past 12 months, Tarsus Pharmaceuticals has paid 0.00 in taxes.

Tarsus Pharmaceuticals EV to EBITDA ratio is -19.34, with an EV/FCF ratio of -24.35.

Tarsus Pharmaceuticals has $407.92M in cash and marketable securities with ― in debt, giving a net cash position of -$407.92M billion.

Gross margin is 92.99%, with operating margin of -65.90%, and net profit margin of -63.16%.

The average price target for Tarsus Pharmaceuticals is $68.38, which is 11.43% higher than the current price. The consensus rating is Strong Buy